Cardiovascular HealthVisceral fat, which surrounds organs deep in the abdomen, was more strongly associated with type 2 diabetes risk than body mass index (BMI) in a study of 36,831 UK Biobank participants published July 15, 2026, in the International Journal of Obesity. A second study, published online July 26 in Adipocyte, compared visceral and subcutaneous fat […]
Read the Full Bite →
Aging & LongevityDeclines in physical function were measurable years before cardiovascular events among older adults, according to a nested case-control study published September 23, 2026, in JAMA Cardiology. Researchers analyzed 12,015 people from the Aspirin in Reducing Events in the Elderly (ASPREE) cohort, including 2,403 who subsequently experienced cardiovascular disease and 9,612 matched controls, and found that […]
Read the Full Bite →
Cancer & OncologyActivating the lipid-sensing transcription factor peroxisome proliferator-activated receptor delta (PPARδ) promoted cancer-cell growth but strengthened tumor-fighting immune cells when activated in a different cellular compartment, according to a study published October 14, 2026, in Nature Immunology. Researchers led by Paul Bunk, Ilgin Ergin and colleagues used genetically modified mouse tumors, immune-cell experiments and engineered human […]
Read the Full Bite →
Clinical Research & TrialsPeople taking glucagon-like peptide-1 (GLP-1) receptor agonists reported nail detachment and discoloration more often than nonusers with obesity or type 2 diabetes in a multinational study presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026. The cross-sectional analysis compared 575 GLP-1 users with 1,329 nonusers across four countries, but it cannot establish […]
Read the Full Bite →
Cancer & OncologyCirculating tumor DNA (ctDNA) testing can identify molecular signs of colorectal cancer recurrence after surgery, but a randomized phase 3 trial published in Nature Medicine in June 2026 found that treating patients solely because their blood test became positive did not significantly improve disease-free survival. In the ALTAIR trial, 243 patients with detectable tumor DNA […]
Read the Full Bite →
Cardiovascular HealthA prospective multicenter cohort found that short-term low-dose glucocorticoids around flow-diverter treatment were associated with fewer major cerebrovascular events and less in-stent stenosis.
Read the Full Bite →
Cardiovascular HealthA European Heart Journal meta-analysis of 87 randomized trials found that higher whole-grain intake modestly improved LDL cholesterol, fasting glucose, blood pressure and other cardiometabolic risk factors.
Read the Full Bite →
Cancer & OncologyA Nature Medicine phase 1 trial found that a personalized neoantigen vaccine generated tumor-specific immune responses in ovarian cancer, with biomarker evidence of biologic activity in 6 of 10 vaccinated patients.
Read the Full Bite →
Clinical Research & TrialsA Nature Medicine study in 13 epilepsy-monitoring patients found that real-time patient feedback reduced seizure-detector false alarms by about 80%.
Read the Full Bite →
Cancer & OncologyA Nature Medicine study of 52,236 adults with cancer found that cachectic weight loss clusters near disease progression and may be predictable using routine clinical and genomic data.
Read the Full Bite →
Clinical Research & TrialsA longitudinal Nature Medicine study found EBV-associated B cell activity rising up to three months before multiple sclerosis relapse, suggesting viral reactivation may help prime attacks.
Read the Full Bite →
Clinical Research & TrialsIn a 10-person NEJM study, optogenetic gene therapy increased light sensitivity in 7 people with advanced retinitis pigmentosa, including clinically meaningful improvement in 6.
Read the Full Bite →
Cell & Molecular BiologyA Neuron study identified a direct amygdala-to-dorsolateral-striatum pathway that strengthens cue-driven grooming and is abnormally active in a mouse model of compulsive behavior.
Read the Full Bite →
Clinical Research & TrialsIn the RESET for Remission randomized trial, 54% of younger adults with obesity and early-onset type 2 diabetes reached remission after a low-energy diet plus structured exercise, compared with 4% receiving usual care.
Read the Full Bite →
Cancer & OncologyA new Nature Communications study identified MPZL1 as a potential CAR-T target in solid tumors and showed tumor regression in multiple preclinical models.
Read the Full Bite →
Clinical Research & TrialsCBL-514 reduced abdominal subcutaneous fat in randomized phase 2 trials and showed an early visceral-fat signal, but it is not yet a proven obesity or weight-loss treatment.
Read the Full Bite →
Clinical Research & TrialsA two-year randomized trial found that diet drinks and water produced equivalent long-term weight-loss outcomes during a behavioral weight-management program.
Read the Full Bite →
Cardiovascular HealthSilent atherosclerosis was already detectable in some adults in their 20s, according to the REACT study published in The New England Journal of Medicine. The study imaged 16,808 adults aged 18 to 70 in Denmark and Spain who had no known atherosclerotic cardiovascular disease and found plaque in 57.1% overall, including 8.7% of men and […]
Read the Full Bite →
Cancer & OncologyThe Phase 3 SOLARIS trial found that high-dose vitamin D3 added to chemotherapy and bevacizumab did not significantly improve progression-free survival in metastatic colorectal cancer.
Read the Full Bite →
Clinical Research & TrialsKamuvudine-9 reversed paralysis and vision loss in a mouse model of multiple sclerosis. Here is what the study showed, and what remains unproven.
Read the Full Bite →
Clinical Research & TrialsRetatrutide has already attracted attention for the amount of weight loss seen in obesity trials. New Phase 3 results now answer a different question: how well can the experimental drug address obesity and high blood sugar at the same time in people with type 2 diabetes? In the TRIUMPH-2 trial, adults with type 2 diabetes […]
Read the Full Bite →
Cancer & OncologyObesity has long been linked to cancers of the colon, kidney, liver, endometrium and several other organs. A major 2026 analysis suggests that the list may be broader than the 13 cancer types commonly highlighted in public-health guidance. Researchers from the National Cancer Institute, Imperial College London and Johns Hopkins University combined evidence from 226 […]
Read the Full Bite →
Aging & LongevityVitamin D, fish oil, and glucosamine are familiar supplements, especially among older adults. In 2026, however, all three have been pulled into an uncomfortable scientific question: could a supplement taken for health actually become less helpful, or even harmful, as the brain ages? Several new studies have reported associations between supplement use and faster cognitive […]
Read the Full Bite →
Clinical Research & TrialsGLP-1 drugs have been linked to hair loss, but the absolute risk is small and rapid weight loss may be part of the explanation. Here is what the evidence shows.
Read the Full Bite →
Cancer & OncologyKRAS mutations drive more than 90% of pancreatic ductal adenocarcinomas (PDAC), yet the protein resisted direct drug development for decades because its surface offered few stable pockets for small molecules and because the mutant protein cycles between active and inactive conformations. That biology is now clinically relevant: a phase 3 trial published in The New […]
Read the Full Bite →
Clinical Research & TrialsRespiratory syncytial virus (RSV) vaccination is now recommended for every U.S. adult age 75 and older and for adults ages 50 to 74 who have a higher risk of severe RSV, according to current Centers for Disease Control and Prevention (CDC) guidance. The recommendation is based on clinical trials and post-licensure evidence showing that vaccination […]
Read the Full Bite →
Cell & Molecular BiologyAlexander disease begins with toxic GFAP buildup in astrocytes. Here is how mutations create Rosenthal fibers, disrupt brain support cells, and led to antisense treatment.
Read the Full Bite →
Cell & Molecular BiologyGLP-1 links the gut, pancreas, stomach, and brain. Here is how the pathway controls blood sugar, appetite, gastric emptying, and weight.
Read the Full Bite →
Clinical Research & TrialsOral and injectable Wegovy use the same drug but differ in dosing, absorption, and convenience. Here is how the evidence compares for obesity treatment.
Read the Full Bite →
Aging & LongevityObesity is linked to changes in brain structure, cognition, and dementia risk, especially in midlife. Here is what recent research shows and what remains uncertain.
Read the Full Bite →
Cardiovascular HealthHepcidin controls how iron moves through the body. In polycythemia vera, that makes iron restriction a way to reduce excess red blood cell production.
Read the Full Bite →
Cancer & OncologyOral SERDs degrade the estrogen receptor and are changing treatment for ESR1-mutated breast cancer. Here is how they differ from aromatase inhibitors, tamoxifen, and fulvestrant.
Read the Full Bite →
Clinical Research & TrialsNirsevimab is designed to cover an RSV season with one dose. Trials show protection for at least 5 months, with hospitalization protection through 180 days.
Read the Full Bite →
Clinical Research & TrialsBeyfortus dosing changes by weight and RSV season. Here is when nirsevimab is given as 50 mg, 100 mg, or 200 mg and who is eligible.
Read the Full Bite →
Cell & Molecular BiologyTYK2 and JAK1 help cytokines activate the JAK-STAT pathway. Here is how selective inhibition differs from broader JAK blockade and why it matters in autoimmune disease.
Read the Full Bite →
Clinical Research & TrialsSemaglutide and tirzepatide reduce lean mass during weight loss, but mostly reduce fat. Here is what DXA studies show about muscle, sarcopenia, and resistance training.
Read the Full Bite →
Cardiovascular HealthThe 2026 AHA/ASA stroke rehabilitation guideline emphasizes earlier therapy, mental health, caregiver support, telehealth, and repeated reassessment across recovery.
Read the Full Bite →
Clinical Research & TrialsIn the SURMOUNT-5 head-to-head obesity trial, tirzepatide produced greater average weight loss than semaglutide at 72 weeks, but the comparison has important limits.
Read the Full Bite →
Cancer & OncologyLiquid biopsy can detect circulating tumor DNA in blood to reveal tumor mutations, treatment resistance, and molecular residual disease, but negative results have important limits.
Read the Full Bite →